 |
|
|
| |
Safety and Efficacy of Glecaprevir/Pibrentasvir for 8 Weeks
for Treatment of Acute Hepatitis C Virus Infection in People Living with HIV
|
| |
| |
CROI 2025 SF March 9-12
Kimberly Workowski1, Barbra Cave2, Pablo Ryan3, John Smith4, Thomas Lutz5, Patrick Lank2, Linda M. Fredrick2, Anne Welhaven2, Dimitri Semizarov2, John Marcinak2, Joseph S. Doyle6
1Department of Medicine, Division of Infectious Diseases, Emory University, Atlanta, GA, USA; 2AbbVie Inc., North Chicago, IL, USA; 3 Internal Medicine, Hospital Universitario Infanta Leonor and CIBERINFEC (ISCIII), Madrid, Spain;
4Digestive & Liver Disease Specialists, Norfolk, VA, USA; 5Infektiologikum Frankfurt, Frankfurt, Germany; 6Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia
|
| |
|
|
|
|
|
